Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline ...

Johnson & Johnson announced new icotrokinra data from a subgroup analysis of ICONIC-LEADa, the first ever Phase 3 registrational study in ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that ...

Icotrokinra demonstrated a favorable safety profile. At Week 16, 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo ...